Younossi, Z. M. et al. The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review. Hepatology 77, 1335–1347 (2023).
Rinella, M. E. et al. A multisociety Delphi consensus statement on new fatty liver disease nomenclature. J. Hepatol. 79, 1542–1556 (2023).
Article CAS PubMed Google Scholar
Loomba, R., Friedman, S. L. & Shulman, G. I. Mechanisms and disease consequences of nonalcoholic fatty liver disease. Cell 184, 2537–2564 (2021).
Article CAS PubMed Google Scholar
Sanyal, A. J. et al. Prospective study of outcomes in adults with nonalcoholic fatty liver disease. N. Engl. J. Med. 385, 1559–1569 (2021).
Article CAS PubMed Google Scholar
Burra, P., Becchetti, C. & Germani, G. NAFLD and liver transplantation: disease burden, current management and future challenges. JHEP Rep. 2, 100192 (2020).
FDA approves first treatment for patients with liver scarring due to fatty liver disease. FDA https://www.fda.gov/news-events/press-announcements/fda-approves-first-treatment-patients-liver-scarring-due-fatty-liver-disease (2024).
Harrison, S. A. et al. A phase 3, randomized, controlled trial of resmetirom in NASH with liver fibrosis. N. Engl. J. Med. 390, 497–509 (2024).
Gawrieh, S. et al. Increases and decreases in liver stiffness measurement are independently associated with the risk of liver-related events in NAFLD. J. Hepatol. 81, 600–608 (2024).
European Association for the Study of the Liver (EASL), European Association for the Study of Diabetes (EASD) & European Association for the Study of Obesity (EASO). Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD). J. Hepatol. 81, 492–542 (2024).
Allen, A. M., Younossi, Z. M., Diehl, A. M., Charlton, M. R. & Lazarus, J. V. Envisioning how to advance the MASH field. Nat. Rev. Gastroenterol. Hepatol. 21, 726–738 (2024).
留言 (0)